Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)

Q: What does CUSIP 98422T100 represent in this 13F holders report?

CUSIP 98422T100 is the security identifier for XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share in Q4 2025?

37 institutional investors reported XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share for Q4 2025. Use the holders table for investor-level position and value details.

CUSIP: 98422T100

Q4 2025 13F Holders as of 31 Dec 2025

Type / Class: Equity / Common Stock, par value $0.0001 per share
Shares outstanding: 73,644,024
Total 13F shares: 39,727,815
Share change: +17,967,980
Total reported value: $25,433,377
Price per share: $0.64
Number of holders: 37
Value change: +$11,324,174
Number of buys: 15
Number of sells: 14

Quarterly Holders Quick Answers

What is CUSIP 98422T100?
CUSIP 98422T100 identifies XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2026
Previous quarter: Q3 2025

Recent filing periods for CUSIP 98422T100:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
GILEAD SCIENCES, INC.	13D/G 13F	Company	20%	14,517,678	$9,581,667	+$2,576,464	31 Dec 2025	13D/G 13F
Point72 Asset Management, L.P.	13D/G	—	9.9%	8,000,000	$6,743,200	+$3,371,600	30 Sep 2025	13D/G
Yekaterina Chudnovsky	3/4/5	10%+ Owner	— class O/S missing	7,000,000	$5,320,000	—	07 Jun 2024	3/4/5
Bain Capital Life Sciences Fund II, L.P.	13D/G	BCLS II Equity Opportunities, LP	8.5%	6,259,742	$4,131,430	$0	31 Dec 2025	13D/G
STEMPOINT CAPITAL LP	13D/G	—	8.4%	6,030,028	$3,979,818	+$1,339,818	31 Dec 2025	13D/G
Bain Capital Life Sciences Investors, LLC	13F 3/4/5	Company · 10%+ Owner	6.2%	4,566,817	$3,848,457	—	30 Sep 2025	13F 3/4/5
Coastlands Capital LP	13D/G	—	10%	5,346,069	$3,742,248	$0	04 Dec 2025	13D/G
AbbVie Inc.	13D/G	—	9%	4,347,826	$3,304,348	$0	11 Feb 2025	13D/G
Frazier Life Sciences Public Fund, L.P.	13D/G	—	6.7%	4,676,472	$3,086,472	-$2,286,600	31 Dec 2025	13D/G
SV7 Impact Medicine Fund LP	3/4/5	10%+ Owner	— class O/S missing	3,227,264	$2,678,630	—	26 Oct 2021	3/4/5
James E. Flynn	3/4/5	Possible Member of 10% Group, 10%+ Owner	— class O/S missing	2,287,944	$1,898,994	—	26 Oct 2021	3/4/5
Atlas Venture Fund XI, L.P.	3/4/5	10%+ Owner	— class O/S missing	2,754,109	$1,762,629	—	08 Feb 2024	3/4/5
FMR LLC	3/4/5 13F	Other* · Company	0.69% from 13F	1,907,670	$1,583,366	—	26 Oct 2021	3/4/5 13F
Merck & Co., Inc.	13F	Company	2%	1,483,758	$1,250,363	—	30 Sep 2025	13F
TAKEDA PHARMACEUTICAL CO LTD	13F 3/4/5	Company · 10%+ Owner	2%	1,475,121	$1,243,084	—	30 Sep 2025	13F 3/4/5
RiverVest Venture Fund IV, L.P.	3/4/5	10%+ Owner	— class O/S missing	1,441,444	$1,196,399	—	26 Oct 2021	3/4/5
VANGUARD GROUP INC	13F	Company	1.7%	1,255,692	$1,058,549	—	30 Sep 2025	13F
Rock Springs Capital Management LP	3/4/5	10%+ Owner	— class O/S missing	1,256,472	$1,042,872	—	26 Oct 2021	3/4/5
BAY CITY CAPITAL LLC	3/4/5	10%+ Owner	— class O/S missing	1,129,490	$937,477	—	26 Oct 2021	3/4/5
MORGAN STANLEY	13F	Company	1.3%	961,917	$810,607	—	30 Sep 2025	13F
AJU IB Investment Co., Ltd.	13F	Company	0.91%	667,742	$595,559	—	30 Sep 2025	13F
Merck KGaA	3/4/5	10%+ Owner	— class O/S missing	680,825	$565,085	—	26 Oct 2021	3/4/5
Rene Russo	3/4/5	PRESIDENT AND CEO, Director	— mixed-class rows	1,914,180 mixed-class rows	$372,363	+$24,680	31 Dec 2025	3/4/5
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.45%	328,972	$277,257	—	30 Sep 2025	13F
Squarepoint Ops LLC	13F	Company	0.45%	328,794	$277,075	—	30 Sep 2025	13F
Trustees of Columbia University in the City of New York	13F	Company	0.34%	249,635	$210,442	—	30 Sep 2025	13F
FIL Ltd	3/4/5	Other*	— class O/S missing	218,705	$181,525	—	26 Oct 2021	3/4/5
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.28%	204,700	$172,501	—	30 Sep 2025	13F
BALYASNY ASSET MANAGEMENT L.P.	13F	Company	0.27%	198,859	$167,578	—	30 Sep 2025	13F
Alexandria Venture Investments, LLC	3/4/5	10%+ Owner	— class O/S missing	166,423	$138,131	—	26 Oct 2021	3/4/5
STATE STREET CORP	13F	Company	0.22%	163,890	$138,110	—	30 Sep 2025	13F
Simon M. Tomlinson	3/4/5	10%+ Owner	— class O/S missing	131,117	$108,827	—	21 Oct 2021	3/4/5
John Charles Williams	3/4/5	10%+ Owner	— class O/S missing	100,080	$83,066	—	21 Oct 2021	3/4/5
Of Ulrich Rodeck Estate	3/4/5	10%+ Owner	— class O/S missing	100,080	$83,066	—	21 Oct 2021	3/4/5
Timothy P. Clackson	3/4/5	10%+ Owner	— class O/S missing	90,956	$75,493	—	21 Oct 2021	3/4/5
TWO SIGMA INVESTMENTS, LP	13F	Company	0.12%	87,790	$73,981	—	30 Sep 2025	13F
Christopher James Frankenfield	3/4/5	Chief Financial Officer	— mixed-class rows	732,305 mixed-class rows	$73,107	-$4,522	31 Dec 2025	3/4/5
Katarina Luptakova	3/4/5	CHIEF MEDICAL OFFICER	— mixed-class rows	518,385 mixed-class rows	$73,002	—	31 Dec 2025	3/4/5
XTX Topco Ltd	13F	Company	0.1%	76,045	$64,083	—	30 Sep 2025	13F
NORTHERN TRUST CORP	13F	Company	0.09%	66,609	$56,131	—	30 Sep 2025	13F
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.08%	56,081	$47,259	—	30 Sep 2025	13F
TWO SIGMA SECURITIES, LLC	13F	Company	0.04%	32,130	$27,076	—	30 Sep 2025	13F
LPL Financial LLC	13F	Company	0.04%	31,000	$26,124	—	30 Sep 2025	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.04%	29,689	$25,019	—	30 Sep 2025	13F
Aptus Capital Advisors, LLC	13F	Company	0.03%	25,000	$21,068	—	30 Sep 2025	13F
Mariner, LLC	13F	Company	0.03%	25,000	$21,068	—	30 Sep 2025	13F
HRT FINANCIAL LP	13F	Company	0.03%	24,736	$20,000	—	30 Sep 2025	13F
Kevin M. Brennan	3/4/5	SVP, FINANCE AND ACCOUNTING	— mixed-class rows	111,592 mixed-class rows	$19,697	-$1,174	31 Dec 2025	3/4/5
SevenBridge Financial Group, LLC	13F	Company	0.03%	25,000	$19,333	—	30 Sep 2025	13F
RAYMOND JAMES FINANCIAL INC	13F	Company	0.03%	18,761	$15,810	—	30 Sep 2025	13F

Institutional Holders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) as of Q4 2025

As of 31 Dec 2025, Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) was held by 37 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 39,727,815 shares. The largest 10 holders included GILEAD SCIENCES, INC., Bain Capital Life Sciences Investors, LLC, Frazier Life Sciences Management, L.P., Point72 Asset Management, L.P., Sio Capital Management, LLC, STEMPOINT CAPITAL LP, Merck & Co., Inc., VANGUARD GROUP INC, Empery Asset Management, LP, and Ghisallo Capital Management LLC. This page lists 37 institutional shareholders reporting positions in this security for the Q4 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders

Q4 2025 holders

Holder diff

Investor	Q3 2025 Shares	Q4 2025 Shares	Share Diff	Share Chg %	Q3 2025 Value $	Q4 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.